Document is current
Any future updates will be listed below
-
Authors
Mollan, S. P.
Wakerley, B. R.
Alimajstorovic, Z.
Mitchell, J.
Ottridge, R.
Yiangou, A.
Thaller, M.
Gupta, A.
Grech, O.
Lavery, G.
Brock, K.
Sinclair, A. J.
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/K015184/1)
National Institute for Health Research (NIHR-CS-011-028)
- License Information
-
More Information
Article History
Received: 6 May 2021
Accepted: 1 September 2021
First Online: 7 October 2021
Declarations
:
: The trial was approved by The National Research Ethics Committee West Midlands – The Black Country, on 28 February 2014 (14/WM/0011). All participants gave written consent after receiving detailed written information. The trial was registered, identifier: .
: All co-authors consent for publication.
: SM - Royalties - Springer publishing: Neuro-Ophthalmology, Global Trends in Diagnosis, Treatment and Management; Consultancy - Invex therapeutics, Neurodiem, Honoraria - Novartis, Santen, Santhera, Allergan, Chuagi, Chiesi; Data safety/advisory boards - Roche, Janssen, Invex therapeutics. BW - Consultancy, Invex Therapeutics; Director Ceftronics Limited; Patent pending, Uk - 1907237.0. ZA – none. JM – none. RO – none. AY - fees for educational talk – TEVA. MT – none. AG – none. OG – none. GL – none. KB - Consultancy, Invex Therapeutics; stock - Astrazenica, GlaxoSmithKline. AS - Honoraria - Chiesi; Safet board/advisory - Novartis; Director / Share options - Invex therapeutics.
